Novartis
Novartis buys dry eye treatment Xiidra in deal worth $5.3 billion
May 9, 2019Business Services, Medical Communications, Sales and Marketing Novartis, Shire, Takeda, debt, pharma, xiidra
Japanese multinational Takeda Pharmaceutical has agreed to sell its dry eye drug Xiidra to Swiss firm Novartis in a deal …
ABPI names Novartis’ Haseeb Ahmad as new President
May 7, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Novartis, appointment, pharma
The Association of the British Pharmaceutical Industry (ABPI) has revealed the appointment of a new President: Haseeb Ahmad will assume …
ABPI names Novartis’ Haseeb Ahmad as new President
May 3, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Novartis, appointment, pharma
The Association of the British Pharmaceutical Industry (ABPI) has revealed the appointment of a new President: Haseeb Ahmad will assume …
Top Ten most popular articles on Pharmafile.com this week!
April 26, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Aduro Biotech, Cancer, GSK, ICR, J&J, JJ, Novartis, Sandoz, pharma
The Institute for Cancer Research (ICR) called for new measures to increase the speed with which patients in the UK …
Senior GSK exec Richard Saynor revealed as new Sandoz CEO
April 25, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, Sandoz, appointment, pharma
Novartis has seen a major leadership change within its business, as the company announced that senior GlaxoSmithKline exec Richard Saynor …
Novartis reveals promising interim Phase 3 data for gene therapy Zolgensma in spinal muscular atrophy
April 18, 2019Research and Development Novartis, Zolgensma, pharma
Novartis has revealed new interim data from its Phase 3 trial investigating the efficacy of its gene therapy Zolgensma (onasemnogene …
Top Ten most popular articles on Pharmafile.com this week!
April 18, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, Genentech, Gilead, HIV, MS, Novartis, kidney disease, pharma
This week was a good one for clinical trials and a bad one for employees after both Gilead and GSK …
Novartis’ Kisqali combo rejected by NICE for advanced breast cancer
April 11, 2019Sales and Marketing Kisqali, NHS, NICE, Novartis, pharma
Novartis’ Kisqali (ribociclib) has been rejected for use on the NHS by NICE for the treatment of advanced breast cancer, …
Top Ten most popular articles on Pharmafile.com this week!
April 5, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, AstraZeneca, Northern Ireland, Novartis, Placebo, UK, brexit, pharma
As Brexit looms, pharma trade lobby the ABPI called for a ban on exports of medicines in the case of …
Novartis’ Cosentyx approved in China for plaque psoriasis
April 2, 2019Manufacturing and Production, Sales and Marketing China, Cosentyx, Novartis, pharma, psoriasis
Novartis has revealed that its interleukin-17A (IL-17A) Cosentyx (secukinumab) has been authorised for use in China in the treatment of …
Novartis must face kickback allegations in court
April 2, 2019Manufacturing and Production Novartis, US, government, kickbacks, prescriptions, whistle blower, whistle-blower
The US government has accused Novartis of paying doctors millions of dollars in kickbacks as part of a “company-wide kickback …
Novartis inks $1.6 billion deal with immunology biotech IFM Therapeutics
April 1, 2019Sales and Marketing Atlas Venture, Boston, IFM Therapeutics, Novartis, pharma
Swiss firm Novartis has agreed to pay a sum of $310 million upfront to Boston inflammation specialist IFM Therapeutics, as …
Novartis’ new MS drug to cost $88,000 a year
March 27, 2019Research and Development, Sales and Marketing FDA, MS, Novartis, Novartis pharmaceuticals, multiple sclerosis
Paul Hudson, the CEO of Swiss firm Novartis Pharmaceuticals has said the company’s newly approved multiple sclerosis (MS) drug will …
Sandoz CEO Richard Francis to step down
March 14, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Novartis, Sandoz, appointment, pharma
Richard Francis is set to step down his role as Chief Executive of Novartis’ generics arm Sandoz after five years’ …
Scottish Medicines Consortium rejects Novartis’ CAR T therapy Kymriah
March 12, 2019Manufacturing and Production Kymriah, NICE, Novartis, SMC, Scotland, UK
Scotland’s cost effectiveness body has refused to fund Novartis’ CAR T therapy Kymriah for adult patients with lymphoma. The Scottish …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
